New Zealand - English - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - hydralazine hydrochloride 25mg - tablet - 25 mg - active: hydralazine hydrochloride 25mg excipient: colloidal silicon dioxide disodium edetate dihydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - hydralazine hydrochloride 50mg - tablet - 50 mg - active: hydralazine hydrochloride 50mg excipient: colloidal silicon dioxide disodium edetate dihydrate magnesium stearate microcrystalline cellulose opadry pregelatinised maize starch purified talc purified water sodium starch glycolate

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alphaceuticals limited , united kingdom - amoxicillin - capsules, hard - 250

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alphaceuticals limited, united kingdom - amoxicillin - capsules, hard - 250

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

United States - English - NLM (National Library of Medicine)

guna spa - alpha-tocopherol (unii: h4n855pnz1) (alpha-tocopherol - unii:h4n855pnz1), laminaria digitata (unii: 15e7c67ee8) (laminaria digitata - unii:15e7c67ee8), botryoglossum platycarpum (unii: pta4328m4z) (botryoglossum platycarpum - unii:pta4328m4z), fucus serratus (unii: v8k40wnw5b) (fucus serratus - unii:v8k40wnw5b), sus scrofa capillary tissue (unii: 253a0356pn) (sus scrofa capillary tissue - unii:253a0356pn), ubidecarenone (unii: ej27x76m46) (ubidecarenone - unii:ej27x76m46), sus scrofa collagen (unii: i - alpha-tocopherol 4 [hp_c] in 4 g - alpha tocopherol        4c    antioxidant brown algae, laminaria        4c    detoxification and drainage brown algae, platycarpus    4c    detoxification and drainage brown algae, serratus        4c    detoxification and drainage capillary tissue        4c    blood flow support coenzyme q-10            4c    antioxidant collagen            4c    eutrophic action fucus vesiculosus        4c    detoxification isoleucine            4c    dermis protein metabolic support knotted wrack            4c    skin tone support leucine                4c    dermis protein metabolic support placenta totalis        4c    vascular stimulation retinol                4c    antioxidant sea lettuce            4c    skin tone selenium metallicum        4c    cell metabolic support skin tissue            4c    eutrophic supp

Ireland - English - HPRA (Health Products Regulatory Authority)

merit pharmaceuticals limited - dutasteride; tamsulosin hydrochloride - capsule, hard - alpha-adrenoreceptor antagonists; tamsulosin and dutasteride

United States - English - NLM (National Library of Medicine)

csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

accensi pty ltd - alpha-cypermethrin - suspension concentrate - alpha-cypermethrin pyrethroid active 50.0 g/l - insecticide - commercial/industrial premises | domestic and/or public area | public health situation | premises - ant | cockroach | flea | fly | silverfish | spider | argentine ant | ctenocephalides spp. | ground fleas | large cockroach | pharaoh ant | small cockroach